Comparative Efficacy and Safety of Topical Bepotastine Besilate 1.5% Versus Sodium Cromoglycate 4% in Chronic Allergic Conjunctivitis: A Prospective Study.
J Ocul Pharmacol TherJun 10, 2026 (epub)
Mayank Jhanwar, Sumit Goyal, Ajay Nathan
✦ AI-curated · Sources linked
In 30 seconds
This randomized controlled trial compared the efficacy and safety of bepotastine besilate 1.5% and sodium cromoglycate 4% in 100 adults with chronic allergic conjunctivitis. After 6 months, bepotastine demonstrated a 74.4% improvement in ocular itching severity, significantly greater than the 63.8% improvement seen with cromolyn (P < 0.01).
Key findings
- Bepotastine led to a 74.4% improvement in ocular itching severity compared to 63.8% for cromolyn (P < 0.01).
- Cromolyn was more effective in reducing conjunctival redness, achieving a 70.0% improvement versus 59.3% for bepotastine.
- Patient compliance and satisfaction were higher in the bepotastine group due to its twice-daily dosing.
Why it matters
Understanding the comparative efficacy and safety of these treatments can guide clinicians in selecting appropriate therapies for patients with chronic allergic conjunctivitis, tailoring choices to individual symptom profiles and preferences.